NPPA Fixes Retail Price Of 25 Formulations, Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, the Government of India has fixed retail prices for 25 formulations including those used to treat high blood pressure, type 2 diabetes, cholesterol, bacterial infections, asthma.This came in line with the decision of the 110th Authority meeting dated...
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, the Government of India has fixed retail prices for 25 formulations including those used to treat high blood pressure, type 2 diabetes, cholesterol, bacterial infections, asthma.
This came in line with the decision of the 110th Authority meeting dated 23.03.2023.
These include Skymap Pharmaceuticals/German Remedies Pharmaceutical's Glimepiride tablets, Akums /Sun Pharmaceutical's Bilastine and Montelukast Orodispersible Tablets, Synokem Pharmaceuticals / Alembic Pharmaceutical's Dapagliflozin & Metformin Hydrochloride (Extended Release) Tablets, Akums/ Emcure Pharmaceutical's Levocetirizine, Montelukast & (SR) Ambroxol Hydrochloride Tablets, Lupin's Bisoprolol Fumarate & Amlodipine Tablets, Akums Drugs & Pharmaceuticals /Glenmark Pharmaceutical's Cilnidipine & Telmisartan Tablets and others.
In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Itraconazole Capsules (Supra- Bioavailable Formulation) | Each Hard Gelatin Capsule contains: Itraconazole BP 130mg | 1 Capsule | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd. | 20.72 |
2 | Telmisartan & Chlorthalidone Tablets | Each uncoated bilayered tablet contains: Telmisartan IP 40mg Chlorthalidone IP 6.25mg | 1 Tablet | M/s Innova Captab Limied / M/s Indoco Remedies Limited | 8.04 |
3 | Camylofin Dihydrochlorid e and Paracetamol Tablets | Each film coated tablet contains: Camylofin Dihydrochloride 50mg Paracetamol IP 325mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd. | 5.53 |
4 | Glimepiride tablets IP | Each uncoated tablet contains: Glimepiride IP 4mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s German Remedies Pharmaceuticals Pvt. Ltd. | 11.57 |
5 | Glimepiride tablets IP | Each uncoated tablet contains: Glimepiride IP 3mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s German Remedies Pharmaceuticals Pvt. Ltd. | 9.77 |
6 | Gliclazide | Each uncoated bilayered | 1 Tablet | M/s Swiss | 6.57 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
(MR) and Metformin Hydrochloride (ER) Tablets | tablet contains: Gliclazide IP 30mg (in MR form) Metformin Hydrochloride IP 500mg (as Extended Release) | Garniers Genexiaa Sciences Pvt. Ltd. / M/s Servier India Pvt. Ltd. | |||
7 | Bilastine and Montelukast Orodispersible Tablets | Each uncoated Orodispersible tablet contains: Montelukast Sodium IP Eq. to Montelukast 10mg Bilastine 20mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Sun Pharmaceuticals Industries Limited | 13.21 |
8 | Chlorpheniram ine Maleate and Phenylephrine Hydrochloride Syrup | Each 5ml contains: Chlorpheniramine Maleate IP 2mg Phenylephrine Hydrochloride IP 5mg | 1 ml | M/s Stedman Pharmaceuticals Pvt. Ltd. | 1.16 |
9 | Dapagliflozin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Metformin Hydrochloride IP (Extended Release) 1000mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Alembic Pharmaceuticals Ltd. | 7.31 |
10 | Dapagliflozin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Metformin Hydrochloride IP (Extended Release) 1000mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Alembic Pharmaceuticals Ltd. | 10.53 |
11 | Dapagliflozin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Metformin Hydrochloride IP (Extended Release) 500mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Alembic Pharmaceuticals Ltd. | 9.10 |
12 | Dapagliflozin and Metformin Hydrochloride (as Extended Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (as Extended Release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Mankind Prime Labs Pvt. Ltd. | 9.10 |
13 | Dapagliflozin and Metformin Hydrochloride (as Extended Release) | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Mankind Prime Labs Pvt. Ltd. | 10.53 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Tablets | Metformin Hydrochloride IP 1000mg (as Extended Release) | ||||
14 | Levocetirizine, Montelukast & (SR) Ambroxol Hydrochloride Tablets | Each uncoated bilayered tablet contains: Levocetirizine Dihydrochloride IP 5mg Montelukast Sodium IP eq. to Anhydrous Montelukast 10mg Ambroxol Hydrochloride IP 75mg (As Sustained Release) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Ltd. | 15.39 |
15 | Omeprazole & Domperidone Capsules IP | Each hard gelatin capsule contains: Omeprazole IP 20mg (as gastro-resistant pellets) Domperidone IP 10mg (as pellets) | 1 Capsule | M/s Innova Captab Ltd. / M/s Torrent Pharmaceuticals Limited | 5.90 |
16 | Combi pack of Clarithromycin Tablets IP, Esomeprazole Tablets IP & Amoxicillin Tablets USP | Each Strip contains:
Each film coated tablet contains: Clarithromycin IP 500mg
Each Enteric coated tablet contains: Esomeprazole Magnesium Trihydrate IP eq. to Esomeprazole 40mg
Each Film coated tablet contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 750mg | Combi Pack of 6 Tablets | M/s Malik Lifesciences Pvt. Ltd. / M/s Zuventus Healthcare Limited | 152.17 |
17 | Bisoprolol Fumarate & Amlodipine Besylate tablets | Each film coated tablet contains: Bisoprolol Fumarate IP 5mg Amlodipine Besylate IP Eq. to Amlodipine 5mg | 1 Tablet | M/s Tha Madras Pharmaceuticals / M/s Cipla Ltd. | 8.34 |
18 | Bisoprolol Fumarate & Amlodipine Besylate tablets | Each film coated tablet contains: Bisoprolol Fumarate IP 2.5mg Amlodipine Besylate IP Eq. to Amlodipine 5mg | 1 Tablet | M/s Tha Madras Pharmaceuticals / M/s Cipla Ltd. | 6.19 |
19 | Erythropoietin Injection BP 6000 IU/ml | Each pre-filled Syringe contains: Erythropoietin Concentrated Solution IP 6000IU Albumin Human IP 2.5mg | 1 Vial | M/s Gennova Biopharmaceutica ls Ltd. / M/s Wockhardt Limited | 1449.7 4 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Sodium Chloride IP 5.8mg Sodium Citrate IP 5.8mg Citric Acid monohydrate IP 5.8mg Water for Injections IP (q.s. to 1ml) | |||||
20 | Glycopyrroniu m Ph. Eur, Formoterol Fumarate IP and Budesonide Inhalation powder | Each Capsule contains: Glycopyrronium Bromide Ph. Eur eq. to Glycopyrronium 25mcg, Formoterol Fumarate (As Formoterol Fumarate Dihydrate IP) 12mcg Budesonide IP 400mcg | 1 Capsule | M/s Lupin Limited | 12.19 |
21 | Bisoprolol Fumarate & Amlodipine Tablets | Each film coated tablet contains: Bisoprolol Fumarate IP 5mg Amlodipine Besylate IP Eq. to Amlodipine 5mg | 1 Tablet | M/s J. K. Printpack /M/s Zydus Healthcare Limited | 8.34 |
22 | Cilnidipine & Telmisartan Tablets | Each film coated tablet contains: Cilnidipine IP 20mg Telmisartan IP 40mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Glenmark Pharmaceuticals Limited | 12.83 |
23 | Ceftazidime and Avibactam powder for concentrate for solution for infusion | Each vial contains: Ceftazidime (as ceftazidime Pentahydrate) IP 2gram Avibactam Sodium eq. to Avibactam 0.5gm | 1 ml | M/s BDR Pharmaceuticals International Pvt. Ltd. / M/s Wockhardt Limited | 3773.3 1 |
24 | Cilnidipine, Telmisartan & Chlorthalidone Tablets | Each film coated tablet contains: Cilnidipine IP 10mg Telmisartan IP 40mg Chlorthalidone IP 6.25mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd. | 13.17 |
25 | ORS with Zinc powder 4.38g | Each sachet of 4.38g contains: Zinc Sulfate Monohydrate IP 0.011g Sodium Citrate IP 0.58g Potassium Chloride IP 0.30g Sodium Chloride IP 0.52g Dextrose Anhydrous IP 2.70g | 1 Sachet | M/s FDC Limited | 6.12 |
The notification further added,
(a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column
(2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd